COMPARATIVE EFFECTIVENESS OF CARDIOVASCULAR DEVICES AND MEDICARE COST GROWTH
心血管设备的比较有效性和医疗保险成本增长
基本信息
- 批准号:7941932
- 负责人:
- 金额:$ 39.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-30 至 2012-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Essential to a complete understanding of the comparative effectiveness of new medical technologies in improving population health care outcomes is a complete elucidation of how new technologies increase national health care costs. New technology is widely considered by health economists to be the leading driver of rising U.S. health care costs, yet the precise mechanisms by which new technologies produce cost growth are uncertain. It is likewise uncertain how local-area health care market factors have affected cost increases due to new technology. Finally, it is not well understood how national policy initiatives such as Medicare's Coverage with Evidence Development program, changes in diagnosis-related group (DRG) assignment, and modifications in DRG reimbursement rates have affected the rate of growth in Medicare costs. Implantable cardiovascular devices are among the most costly therapies covered by the Medicare program, and recent Centers for Medicare and Medicaid Services coverage decisions for drug-eluting coronary stents (2003) and carotid arterial stents (2004), as well as expansions of coverage indications for implantable cardioverter defibrillators (2003 and 2005), potentially have entailed billions of dollars in additional annual expenditures for the Medicare program. As such, a clearer understanding of how the introduction of these devices into clinical practice affected Medicare cost growth can critically inform the forecasting of future Medicare expenditures, and thus inform decisions regarding the comparative effectiveness of these new technologies (and similar, future innovations) relative to costs. In this project, we will analyze national Medicare claims data from 2001- 2008 in pursuit of the following goals: (1) to measure the degree to which these 3 new cardiovascular technologies have increased Medicare expenditures, and to assess the proportion of the cost growth that can be attributed to the increases in the direct cost of the technology, expansion in the volume of care, changes in the characteristics of patients undergoing treatment, increases in complementary health care expenditures, and changes in downstream costs; (2) to determine how cost growth due to these 3 new cardiovascular technologies has varied across small geographic areas, and to assess the proportion of technology-related cost growth that is attributable to market-level factors such as the intensity of hospital competition, the presence of cardiac specialty hospitals within a health care market, or the presence of hospitals there were involved in clinical trials of the devices; and (3) to explore how differences in Medicare's coverage decisions and policies regarding these three technologies, including differing institutional requirements for reimbursement as well as variation in the use of new diagnosis-related groups for hospital reimbursement, affected growth in Medicare costs.
描述(由申请人提供):要全面了解新医疗技术在改善人口卫生保健结果方面的相对有效性,就必须全面阐明新技术如何增加国家卫生保健成本。健康经济学家普遍认为,新技术是美国医疗保健成本上升的主要驱动因素,但新技术导致成本增长的确切机制尚不确定。同样不确定的是,当地医疗保健市场因素如何影响新技术带来的成本增加。最后,国家政策举措,如医疗保险的证据开发覆盖计划、诊断相关组(DRG)分配的变化以及DRG报销率的修改,如何影响医疗保险成本的增长率,目前还不清楚。植入式心血管装置是医疗保险计划中最昂贵的治疗方法之一,最近医疗保险和医疗补助服务中心决定覆盖药物洗脱冠状动脉支架(2003年)和颈动脉支架(2004年),以及植入式心律转复除颤器(2003年和2005年)的覆盖适应症,潜在地为医疗保险计划带来数十亿美元的额外年度支出。因此,更清楚地了解将这些设备引入临床实践如何影响医疗保险成本增长,可以为预测未来医疗保险支出提供关键信息,从而为有关这些新技术(以及类似的未来创新)相对于成本的相对有效性的决策提供信息。在这个项目中,我们将分析2001年至2008年的国家医疗保险索赔数据,以实现以下目标:(1)衡量这3种心血管新技术增加医疗保险支出的程度,并评估成本增长可归因于技术直接成本的增加、护理量的扩大、接受治疗的患者特征的变化、补充医疗支出的增加和下游成本变化的比例;(2)确定由于这3种新的心血管技术而导致的成本增长如何在小的地理区域内变化,并评估可归因于市场层面因素的技术相关成本增长的比例,如医院竞争的强度、医疗保健市场中心脏专科医院的存在,或参与设备临床试验的医院的存在;(3)探讨关于这三种技术的医疗保险覆盖决策和政策的差异,包括不同的报销机构要求以及医院报销新诊断相关组的使用差异,如何影响医疗保险成本的增长。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER W. GROENEVELD其他文献
PETER W. GROENEVELD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER W. GROENEVELD', 18)}}的其他基金
Impact of the MISSION Act on Quality and Outcomes of Interventional Cardiology and Cardiac Surgery among Veterans
《使命法案》对退伍军人介入心脏病学和心脏手术的质量和结果的影响
- 批准号:
10640085 - 财政年份:2022
- 资助金额:
$ 39.25万 - 项目类别:
Postdoctoral Training in Health Services Research
卫生服务研究博士后培训
- 批准号:
10747140 - 财政年份:2018
- 资助金额:
$ 39.25万 - 项目类别:
Costs and Outcomes of Chronic Heart Disease Care in the VHA
VHA 中慢性心脏病护理的成本和结果
- 批准号:
9888301 - 财政年份:2015
- 资助金额:
$ 39.25万 - 项目类别:
Costs and Outcomes of Chronic Heart Disease Care in the VHA
VHA 中慢性心脏病护理的成本和结果
- 批准号:
9015267 - 财政年份:2015
- 资助金额:
$ 39.25万 - 项目类别:
Market and Organization Impact on Medical Technology Diffusion: Outcomes and Value
市场和组织对医疗技术传播的影响:结果和价值
- 批准号:
8800457 - 财政年份:2014
- 资助金额:
$ 39.25万 - 项目类别:
Impact of New Technologies on Chronic Heart Failure Outcomes and Costs in the VHA
新技术对 VHA 慢性心力衰竭结果和成本的影响
- 批准号:
8292934 - 财政年份:2011
- 资助金额:
$ 39.25万 - 项目类别:
Impact of New Technologies on Chronic Heart Failure Outcomes and Costs in the VHA
新技术对 VHA 慢性心力衰竭结果和成本的影响
- 批准号:
8084752 - 财政年份:2011
- 资助金额:
$ 39.25万 - 项目类别:
COMPARATIVE EFFECTIVENESS OF CARDIOVASCULAR DEVICES AND MEDICARE COST GROWTH
心血管设备的比较有效性和医疗保险成本增长
- 批准号:
8120891 - 财政年份:2009
- 资助金额:
$ 39.25万 - 项目类别:
COMPARATIVE EFFECTIVENESS OF CARDIOVASCULAR DEVICES AND MEDICARE COST GROWTH
心血管设备的比较有效性和医疗保险成本增长
- 批准号:
7785491 - 财政年份:2009
- 资助金额:
$ 39.25万 - 项目类别:
Racial Differences in BRCA1/2 Testing: Patients or Providers?
BRCA1/2 检测中的种族差异:患者还是提供者?
- 批准号:
8471069 - 财政年份:2009
- 资助金额:
$ 39.25万 - 项目类别:
相似海外基金
In-Vitro evaluation of the effectiveness of a novel Dual Drug Coated Balloon catheter to treat Vascular and cardiovascular diseases
新型双药物涂层球囊导管治疗血管和心血管疾病有效性的体外评估
- 批准号:
10109618 - 财政年份:2024
- 资助金额:
$ 39.25万 - 项目类别:
Launchpad
Nirmatrelvir/ritonavir (Paxlovid) in the prevention of long-term cardiovascular outcomes: The paxloviD Effectiveness For the prEvention of loNg coviD (DEFEND) clinical trial.
Nirmatrelvir/ritonavir (Paxlovid) 预防长期心血管结局:paxlovid 对于预防长期新冠病毒 (DEFEND) 的有效性临床试验。
- 批准号:
494291 - 财政年份:2023
- 资助金额:
$ 39.25万 - 项目类别:
Operating Grants
Heterogeneity and Generalizability of the effectiveness of intensive blood pressure control to prevent cardiovascular events.
强化血压控制预防心血管事件的有效性的异质性和普遍性。
- 批准号:
21K20900 - 财政年份:2021
- 资助金额:
$ 39.25万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Determining if implementation of the haptoglobin phenotype biomarker should be tested in type 2 diabetes treatment planning to prevent cardiovascular disease: a biostatistical analysis, a cost-effectiveness analysis, and a patient priority analysis
确定是否应在 2 型糖尿病治疗计划中测试触珠蛋白表型生物标志物的实施以预防心血管疾病:生物统计分析、成本效益分析和患者优先分析
- 批准号:
458643 - 财政年份:2021
- 资助金额:
$ 39.25万 - 项目类别:
Studentship Programs
The long-term effectiveness of a peer-led lifestyle intervention program on diabetes progression and cardiovascular risk: the Kerala Diabetes Prevention Program in India.
由同伴主导的生活方式干预计划对糖尿病进展和心血管风险的长期有效性:印度喀拉拉邦糖尿病预防计划。
- 批准号:
nhmrc : GNT1160283 - 财政年份:2019
- 资助金额:
$ 39.25万 - 项目类别:
Project Grants
Real-World Evaluation of the Efficacy, Safety and Cost-Effectiveness of Statins for Primary Prevention of Cardiovascular Disease Among the Elderly - A Causal Perspective to Treatment Trajectory Analysis
他汀类药物用于老年人心血管疾病一级预防的有效性、安全性和成本效益的真实世界评价——治疗轨迹分析的因果视角
- 批准号:
402053 - 财政年份:2019
- 资助金额:
$ 39.25万 - 项目类别:
Operating Grants
Cost-effectiveness of cardiovascular disease prevention in HIV care: a systems science approach
艾滋病毒护理中心血管疾病预防的成本效益:系统科学方法
- 批准号:
10661850 - 财政年份:2019
- 资助金额:
$ 39.25万 - 项目类别:
Cost-effectiveness of cardiovascular disease prevention in HIV care: a systems science approach
艾滋病毒护理中心血管疾病预防的成本效益:系统科学方法
- 批准号:
10219503 - 财政年份:2019
- 资助金额:
$ 39.25万 - 项目类别:
An Electronic System for Individualized Monitoring of Patient Reported Outcomes for Value and Effectiveness in Cardiovascular Care (IMPROVE CV Care)
用于个体化监测患者报告结果的心血管护理价值和有效性的电子系统(IMPROVE CV Care)
- 批准号:
407114 - 财政年份:2019
- 资助金额:
$ 39.25万 - 项目类别:
Operating Grants
Cost-effectiveness of cardiovascular disease prevention in HIV care: a systems science approach
艾滋病毒护理中心血管疾病预防的成本效益:系统科学方法
- 批准号:
10449270 - 财政年份:2019
- 资助金额:
$ 39.25万 - 项目类别: